register

News & Trends - Pharmaceuticals

MSD’s latest data to set new standard of care in kidney cancer therapy

Health Industry Hub | June 15, 2021 |
[Total: 1    Average: 5/5]

Pharma News: Immunotherapy after surgery significantly improved disease-free survival (DFS) for patients with the most common type of kidney cancer, clear-cell renal carcinoma (RCC).

A phase III international study, presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, found that MSD’s checkpoint inhibitor Keytruda (pembrolizumab) could offer an effective treatment for patients currently with few other options.

KEYNOTE-564 is the first phase III study with a checkpoint inhibitor in the adjuvant setting to improve DFS for patients with high risk fully resected RCC.

“Despite surgery, recurrence is common in clear-cell renal cell carcinoma, and should it recur, there are limited curative treatment options for patients. Given the success of pembrolizumab in the KEYNOTE-564 trial, this population may soon have a new standard of care,” said ASCO Chief Medical Officer and Executive Vice President Julie R. Gralow, MD, FACP, FASCO.

At the study’s first interim analysis with 24 months median follow-up, the risk of disease recurrence or death was reduced by 32% compared with placebo. The 24-month estimated DFS rate was 77.3% with pembrolizumab, compared to 68.1% with placebo. Overall, DFS benefit was consistent across subgroups.

The estimated preliminary OS rate at 24 months was 96.6% with pembrolizumab and 93.5% with placebo.

“Pembrolizumab may provide a promising treatment for patients for whom there are few therapy options. KEYNOTE-564’s disease-free survival supports pembrolizumab as a potential new standard of care in the adjuvant setting to delay disease recurrence for patients with fully resected clear cell RCC,” said lead author Tony Choueiri, MD, who heads the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute.

Kidney cancer is common in both men and women. Most patients present with local disease, but up to 40% develop metastatic disease following surgery.

Surgical removal of the tumor by partial nephrectomy or the entire kidney by radical nephrectomy is commonly used to treat RCC. However, patients with intermediate- to high-risk advanced disease are at risk for relapse. Currently, there are no standard treatment options post-surgery.


Medical

Medical Pharma Biotech MedTech - Achieving gender equity for female researchers - Professor Julie Campbell, GSK award winner

Achieving gender equity for female researchers – Professor Julie Campbell, GSK award winner

Health Industry Hub | August 6, 2021 |

Medical News: GSK Australia Award for Research Excellence (ARE) is one of the most prestigious and long-standing awards available to […]

More


News & Trends - Medical Technology

MedTech News - Baxter Healthcare launches on-site pop-up COVID vaccination clinic

Baxter launches on-site pop-up COVID vaccination clinic

Health Industry Hub | August 6, 2021 |

MedTech News: Baxter Healthcare has launched an on-site pop-up vaccination clinic at its Western Sydney site this week to support […]

More


News & Trends - Pharmaceuticals

Pharma News - Cancer treatments minimally impacted during COVID-19 lockdowns in Australia, new study

Cancer treatments minimally impacted during COVID-19 lockdowns in Australia, new study

Health Industry Hub | August 6, 2021 |

Pharma News: Australian cancer patients kept up their pharmaceutical treatments during last year’s COVID-19 lockdowns, a big data study from […]

More


News & Trends - Pharmaceuticals

Pharma News - Could PARP inhibitors benefit more ovarian cancer patients?

Could PARP inhibitors benefit more ovarian cancer patients?

Health Industry Hub | August 6, 2021 |

Pharma News: Researchers have made a discovery that could help more Australian women with ovarian cancer gain access to game-changing […]

More